---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-000725"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:57:39.269283+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics announces 2023 priorities, Phase 1 data expected in 2H 2023 for CFT7455 and CFT8634

## Summary
- Cash, cash equivalents and marketable securities of $366M as of Sep 30, 2022; expected to fund operations to end of 2024.
- Phase 1/2 trial of CFT7455 (IKZF1/3 degrader for multiple myeloma) continues; Phase 1 dose escalation data expected in 2H 2023.
- Phase 1/2 trial of CFT8634 (BRD9 degrader for synovial sarcoma) continues; Phase 1 data expected in 2H 2023; PK/PD data supportive of proof of mechanism.
- Phase 1/2 trial of CFT1946 (BRAF-V600 degrader for solid tumors) initiated; IND submission for CFT8919 (EGFR L858R NSCLC) planned in 1H 2023.

## SEC filing metadata
- accession: 0001628280-23-000725
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828023000725/0001628280-23-000725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828023000725/cccc-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-000725
- JSON: https://secwatch.observer/filing/0001628280-23-000725.json
- Plain text: https://secwatch.observer/filing/0001628280-23-000725.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.